

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Pharmaron Beijing Co., Ltd.**

### **康龍化成(北京)新藥技術股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 3759)**

## **CHANGE OF COMPANY SECRETARY, AUTHORISED REPRESENTATIVE AND PROCESS AGENT**

The board of directors (the “**Board**”) of Pharmaron Beijing Co., Ltd. (康龍化成(北京)新藥技術股份有限公司) (the “**Company**”) announces that Ms. Mak Po Man Cherie (“**Ms. Mak**”) has tendered her resignation as the company secretary of the Company (the “**Company Secretary**”) and has ceased to act as an authorised representative of the Company (the “**Authorised Representative**”) under Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the process agent for the acceptance of service of process and notices on behalf of the Company in Hong Kong under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the “**Process Agent**”) with effect from April 25, 2024.

Ms. Mak has confirmed that she has no disagreement with the Board and there is no matter in relation to her resignation that needs to be brought to the attention of the shareholders of the Company and the Stock Exchange.

The Board further announces that Mr. Yim Lok Kwan (“**Mr. Yim**”) has been appointed as the Company Secretary, the Authorised Representative and the Process Agent with effect from April 25, 2024.

Mr. Yim is an assistant vice president of SWCS Corporate Services Group (Hong Kong) Limited and has over 10 years of experience in the corporate secretarial field. He is a fellow member of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute in the United Kingdom, and he holds a bachelor's degree in accounting from Hong Kong Shue Yan University and a master's degree in corporate governance from The Hong Kong Polytechnic University.

The Board would like to take this opportunity to express its gratitude to Ms. Mak for her contribution to the Company during her tenure of service and to welcome Mr. Yim on his new appointment.

By order of the Board  
**Pharmaron Beijing Co., Ltd.**  
康龍化成(北京)新藥技術股份有限公司  
**Dr. Lou Boliang**  
Chairman

Beijing, the PRC  
April 25, 2024

*As at the date of this announcement, the Board of Directors comprises Dr. Lou Boliang, Mr. Lou Xiaoqiang and Ms. Zheng Bei as executive Directors; Mr. Hu Baifeng and Mr. Li Jiaqing as non-executive Directors; Mr. Zhou Qilin, Ms. Li Lihua, Mr. Tsang Kwan Hung Benson and Mr. Yu Jian as independent non-executive Directors.*